-
Tytuł:
-
The effect of benznidazole dose among the efficacy outcome in the murine animal model. A quantitative integration of the literature.
-
Autorzy:
-
Molina I; Tropical Medicine Unit, Infectious Disease Department. PROSICS (International Health Program of the Catalan Health Institute), Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil. Electronic address: .
Perin L; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
Aviles AS; Tropical Medicine Unit, Infectious Disease Department. PROSICS (International Health Program of the Catalan Health Institute), Hospital Universitario Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
de Abreu Vieira PM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Laboratório de Morfopatologia, Departamento de Ciências Biológicas, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
da Silva Fonseca K; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
Cunha LM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
Carneiro CM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil.
-
Źródło:
-
Acta tropica [Acta Trop] 2020 Jan; Vol. 201, pp. 105218. Date of Electronic Publication: 2019 Oct 11.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Amsterdam : Elsevier
Original Publication: Basel.
-
MeSH Terms:
-
Chagas Disease/*drug therapy
Nifurtimox/*pharmacology
Nifurtimox/*therapeutic use
Nitroimidazoles/*pharmacology
Nitroimidazoles/*therapeutic use
Trypanocidal Agents/*therapeutic use
Trypanosoma cruzi/*drug effects
Animals ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Humans ; Mice
-
Contributed Indexing:
-
Keywords: Animal model; Benznidazole; Chagas disease; Clinical trial; Trypanosoma cruzi
-
Substance Nomenclature:
-
0 (Nitroimidazoles)
0 (Trypanocidal Agents)
M84I3K7C2O (Nifurtimox)
YC42NRJ1ZD (benzonidazole)
-
Entry Date(s):
-
Date Created: 20191015 Date Completed: 20200213 Latest Revision: 20200213
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.actatropica.2019.105218
-
PMID:
-
31610148
-
Despite more than 100 years since it was firstly described Chagas disease, only two drugs are available to treat Chagas disease: Nifurtimox launched by Bayer in 1965 and benznidazole launched by Roche in 1971. Drug discovery initiatives have been looking for new compounds as an alternative to these old drugs. Although new platforms have been used with the latest technologies, a critical step on that process still relies on the in vivo model. Unfortunately, to date, available animal models have limited predictive value and there is no standardization. With the aim to better understand the role of benznidazole, the current standard of care of Chagas disease, we performed this review. We intend to analyze the influence of the experimental design of the most used animal model, the murine model, in the assessment of the efficacy endpoint.
(Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
